# Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation

> **NCT01120366** · PHASE4 · COMPLETED · sponsor: **SURPRISE Study Group** · enrollment: 233 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab plus methotrexate
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01120366
- **Lead sponsor:** SURPRISE Study Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01120366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01120366, "Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01120366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*